PDS Biotechnology (NASDAQ:PDSB) Announces Earnings Results

PDS Biotechnology (NASDAQ:PDSB) released its earnings results on Thursday. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.08, Zacks reports.

PDS Biotechnology Stock Performance

Shares of PDSB opened at $1.26 on Friday. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a 52-week low of $1.13 and a 52-week high of $4.42. The company has a 50-day simple moving average of $1.40 and a 200-day simple moving average of $2.16. The company has a market capitalization of $48.12 million, a PE ratio of -1.09 and a beta of 1.68.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their price objective on shares of PDS Biotechnology from $21.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $9.00.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.